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ABSTRACT: A potent class of indolinyl-thiazole based
inhibitors of cellular lipid uptake mediated by scavenger
receptor, class B, type I (SR-BI) was identiﬁed via a high-
throughput screen of the National Institutes of Health
Molecular Libraries Small Molecule Repository (NIH
MLSMR) in an assay measuring the uptake of the ﬂuorescent
lipid DiI from HDL particles. This class of compounds is
represented by ML278 (17−11), a potent (average IC50 = 6
nM) and reversible inhibitor of lipid uptake via SR-BI. ML278
is a plasma-stable, noncytotoxic probe that exhibits moderate
metabolic stability, thus displaying improved properties for in vitro and in vivo studies. Strikingly, ML278 and previously
described inhibitors of lipid transport share the property of increasing the binding of HDL to SR-BI, rather than blocking it,
suggesting there may be similarities in their mechanisms of action.
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The inverse correlation between human plasma HDLcholesterol (HDL-C) levels and risk for adverse events
from atherosclerotic coronary artery disease (CAD)1,2 has
generated considerable interest in developing novel therapies
that increase HDL-C levels by several diﬀerent mechanisms,3
most prominently by cholesteryl ester transfer protein (CETP)
inhibition.4 Despite massive investments in the clinical study of
these inhibitors, the strategy of decreasing CAD risk by
artiﬁcially boosting HDL-C levels has yet to be validated, and
our understanding of lipid traﬃcking and regulation remains
incomplete. New pharmacologic tools that selectively modulate
HDL-C via diﬀerent targets would be valuable for in vitro
mechanistic studies and in vivo functional analyses. Here we
attempted to identify compounds that can modulate the actions
of scavenger receptor, class B type I (SR-BI),5 a mammalian
high density lipoprotein (HDL) receptor that binds HDL
particles on the cell surface and mediates transport of
unesteriﬁed cholesterol (UC) or cholesteryl esters (CE).
Unlike LDL-receptor mediated uptake of lipids, this process
is independent of endocytosis.5,6 In vivo, the structure and
composition of plasma HDL and the metabolic fates of its
cholesterol are controlled by SR-BI.7 In fact, SR-BI has
important inﬂuences on the gastrointestinal, endocrine, and
reproductive systems, as well as development, inﬂammation/
host defense, hepatitis C virus (HCV) infection, and
cardiovascular physiology.7−13
Thus, SR-BI is an interesting drug target, particularly for
compounds that may modulate cholesterol levels or inhibit
HCV infection. However, despite several informative, mecha-
nistic studies14−16 the precise details of HDL recognition by
SR-BI and consequent lipid uptake and eﬄux remain unclear;
new chemical probes may help further our understanding of
these processes.17
We and others have previously discovered small molecule
inhibitors of SR-BI (some examples in Figure 1), which have
subsequently proven to be valuable tools in the study of the
activities of SR-BI in vitro and in vivo, including lipid transport
and lipoprotein metabolism (BLTs,18 HDL376,19,20 R-
13832921) and HCV infection (ITX-506122,23). Unfortunately,
the reported disadvantages of these tool compounds limit their
utility, including toxicity (BLT-1), weak potency (BLT-3, BLT-
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4), speciﬁcity (mitogen-activated protein kinase activity; ITX-
5061), and potential safety issues for humans (HDL376). ITX-
5061 also recently showed disappointing results in a Phase 1b
clinical trial.24 It would be valuable to identify additional potent
SR-BI chemical modulators that lack detrimental side eﬀects25
and that might selectively modulate lipid uptake or eﬄux.
Under the auspices of the NIH’s Molecular Libraries Probe
Production Centers Network (MLPCN), we used a high-
throughput screening approach to identify potent SR-BI
modulators with low toxicities and favorable physicochemical
properties that may be useful as in vitro and in vivo probes of
SR-BI mechanism and function, and that might also be
promising lead compounds for drug discovery. The screen
involved measuring the eﬀects of cellular uptake of the
ﬂuorescent lipid 1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocar-
bocyanine perchlorate (DiI) from HDL particles into CHO
cells overexpressing mouse SR-BI (ldlA[mSR-BI]).26 An initial
probe report is available,27 and assay data may be found in the
PubChem database (http://pubchem.ncbi.nlm.nih.gov, AID
488952).
Of the 319,533 compounds tested in duplicate at 12.5 μM,
3046 compounds (0.96%) reduced cellular ﬂuorescence with
inhibition of ≥70% of that of 1 μM BLT-1, the positive control
and one of the most potent inhibitors readily available. Hit
compounds that were on plates with Z′ < 0.3 or that were
active in 10% or more of the HTS assays listed in PubChem
were eliminated as either unreliable or too nonspeciﬁc. From
the primary screen, a variety of scaﬀolds was veriﬁed to inhibit
DiI uptake with IC50s of <1 μM. Here, 127 out of 186 of the
selected hits that showed dose-dependent inhibition of DiI
uptake were rejected for further study because secondary
screening established that they quench the intrinsic ﬂuores-
cence of DiI in DiI-HDL. We describe here our structure−
activity analysis of one of the most potent scaﬀolds, represented
by the commercially available indolinyl-thiazole 5−1, with an
IC50 of 0.047 μM (Table 1). This scaﬀold was chosen for
further analysis in part for its modularity and synthetic
tractability and for its lack of measurable toxicity after
incubation with CHO cells for 24 h. Furthermore, 5−1
appeared to lack nonselective behavior based on data in
PubChem.28
We explored structure−activity relationships (SAR) of the
scaﬀold by ﬁrst varying the N-substituent of the aminothiazole.
The indolinyl-aminothiazole core of 5−1 was prepared via a
simple 3-step sequence (Scheme 1). Indoline 1 was acylated
with propionyl chloride, and the resulting amide 2 was
subjected to Friedel−Crafts acylation with chloroacetyl
chloride. The chloroketone 3 was condensed with thiourea to
provide the desired aminothiazole 4. The poor solubility and
nucleophilicity of 4 required heating with the acid chloride
coupling partners for optimal preparation of a series of amide
derivatives of 5 (Table 1). Caution should be taken with the
interpretation of the SAR analysis in this series, as the
compounds nearly all have measured solubility in PBS of <1
μM. Despite these issues, the top compounds in this report
showed reproducible inhibition and were very potent, providing
low nanomolar IC50 values.
Scheme 1. Synthesis of Amide Analogues
Figure 1. Some reported inhibitors of SR-BI.
Table 1. Amide Analogues
aAverage of at least two measurements in DiI uptake assay; ±standard
error of mean when n > 2. bInsoluble in DMSO. NT = not tested.
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A number of heterocyclic analogues (Table 1, 5−2−5−14)
were examined to ﬁnd a replacement for the furan of 5−1,
which is a potential toxicophore.29 None of these compounds
provided a level of inhibition comparable to 5−1. A number of
aliphatic (5−15) and aromatic (5−16−5−26) analogues were
prepared, and analogues with a 3-alkoxybenzene substituent
(5−21, 5−23, 5−24, 5−26) provided high levels of inhibition
with IC50s in the range of 30 to 120 nM.
We next modiﬁed the central heterocyclic ring, as well as the
adjacent amide functionality (Table 2). The parent amino-
thiazole 4 showed poor activity. N-Methylation of 5−24 (6) or
reduction of the amide (7) gave compounds with attenuated
activity. A number of heterocyclic replacements for the central
thiazole were prepared, including oxazole 8, imidazole 9, and
1,2,4-oxadiazole 10. The activities sharply decreased in all cases.
A 5-methyl group was tolerated on the thiazole (11), which
may decrease the potential of thiazole ring oxidation by CYP
enzymes to give toxic metabolites.30 Compound 11 also
demonstrates that a triﬂuoromethoxy group could be a
potential replacement of the 3-methoxy substituent.
SAR studies were continued by modifying the indoline N-
substituent; a representative synthesis is provided in Scheme 2.
Protection of the indoline nitrogen with a phenylsulfonyl group
provided an intermediate (12) that underwent Friedel−Crafts
acylation with chloroacetyl chloride to yield ketone 13 in high
yield. The sulfonamide could be hydrolyzed in the presence of
the chloroketone by heating in sulfuric acid. The resulting
indoline 14 was subsequently condensed with thiourea to
generate a 2-aminothiazole, which reacted with Boc2O
exclusively at the indoline nitrogen to generate carbamate 15.
The free amine of 15 was acylated with the desired acid
chlorides, the Boc group was removed with TFA, and the
indoline nitrogen was acylated to provide compounds 17
(Table 3).
Removal of (17−1) or shortening (17−2) the indolinyl acyl
group of 5−24 did not improve activity; whereas, the addition
of a methyl group to the ethyl chain of compound 5−1 (17−3)
decreased potency. The sulfonamides 17−4 and 17−5 showed
an approximately 10-fold drop in potency relative to 5−24, and
the N-allyl indoline 17−6 showed only weak inhibition. More
positive results were obtained with compounds 17−7 to 17−
11. Both smaller and bulkier substituents were well tolerated
with compounds possessing the western 3,5-dimethoxybenzene
moiety. The N-Boc compound 17−8 showed excellent potency
Table 2. Functional Group Modiﬁcations and Central Ring
SAR
aAverage of at least two measurements in DiI uptake assay; ±standard
error of mean when n > 2.
Table 3. Modiﬁcations to Indolinyl Amide
aAverage of at least two measurements in DiI uptake assay; ±standard
error of mean when n > 2.
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in the DiI-uptake assay (4 nM), as did the urea 17−9 (2 nM)
and the methoxyacetamide 17−11 (6 nM).
Modiﬁcations to the indoline ring itself were also examined.
A selection of our results is provided in the Supporting
Information (Table S1). A range of anilines and oxindoles
showed good to excellent potencies, though none were superior
to the top indoline compounds, and they also suﬀered from
very low solubilities (<1 μM).
Several of our more promising compounds were proﬁled in
secondary assays to gain insights into the mode of action and
potential for further development of the indolinyl-thiazole
compound class. None of the compounds showed any
signiﬁcant cytotoxicity after incubation with the ldlA[mSR-BI]
cells for 24 h, and in fact compounds 6 (CC50 = 15 μM) and
17−10 (CC50 = 20 μM) were the only ones with measurable
cytotoxicities.31 Solubility is an issue with this series of
compounds, as all of the compounds tested with low
nanomolar IC50s have solubilities of <1 μM. The methox-
yacetamide 17−11 showed excellent potency (IC50 = 6 nM),
measurable solubility (0.57 μM), and excellent stability in
human plasma (>99% remaining after 5 h, with 94% plasma
protein-bound). Compound 17−11 was nominated as a probe
(ML278) as part of the NIH Molecular Libraries Probe
Production Centers Network (MLPCN) initiative.
Additional mechanistic studies with ML278 were performed
to obtain details on its mode of action. First, in experiments
where cells were pretreated with ML278 for 2 h, washed
extensively with PBS, and then incubated with DiI-HDL,
sharply reduced levels of inhibition were observed. This
demonstrates that the inhibitory action of ML278 is reversible.
In addition to inhibiting the selective uptake of the synthetic
lipid tracer DiI from HDL into ldlA[m-SR-BI] cells (Table 3
and Figure 2, left frame), ML278 inhibited uptake of the
physiological relevant [3H]labeled cholesteryl oleate ester
([3H]CE) from [3H]CE-HDL (calculated IC50 = 7 nM,
Supporting Information Figure S1). Its potency in these assays
is far greater than the clinical compound ITX-5061 (IC50 = 0.94
μM, see comparison in Supporting Information Table S2). We
also showed that, as was the case for BLT-1 and other SR-BI
inhibitors, ML278 enhanced the binding of ﬂuorescent
Alexa448-HDL to SR-BI (EC50 = 0.035 μM) (Figure 2, right
frame). Thus, ML278 joins a growing list of small molecules
that inhibit lipid transport mediated by SR-BI yet increase the
binding of HDL to SR-BI.18
The potential utility of ML278 as a probe for in vivo studies
was investigated by measuring its metabolic stability in the
presence of liver microsomes (Supporting Information Table
S2). The compound shows moderate stability, with 75%
remaining after 1 h incubation with CD-1 mouse liver
microsomes and 48% remaining with human liver microsomes.
Additionally, competitive binding studies were performed with
a panel of 67 diﬀerent receptors and secondary targets
Scheme 2. Representative Synthesis of Analogues with Alternative Indoline N-Substituents
Figure 2. DiI-HDL uptake assay with ML278 (left); Alexa488-HDL binding assay with ML278 (right).
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(Euroﬁns Panlabs). At a concentration of 10 μM, 11 targets
were inhibited by 20% or more, with the highest level of
inhibition observed with the Adenosine A3 receptor (43%
inhibition).
In summary, potent inhibitors of SR-BI-mediated lipid
uptake were discovered as part of the NIH Molecular Libraries
Program. Proﬁling of several top compounds led to the
nomination of the indolinyl-thiazole 17−11 (ML278) as a
probe compound. SAR studies demonstrated that the thiazole
of ML278 was required for activity, ﬂanked by a benzamide,
optimally with a 3-methoxy substituent. ML278 shows superior
potency in the uptake of the synthetic lipid tracer DiI, as well as
[3H]CE, compared to the prior art compounds BLT-1 and
ITX-5061. ML278 also shows no cytotoxicity, has no signiﬁcant
chemical liabilities, shows reversible inhibition, and appears to
act selectively at SR-BI. Additionally, it has excellent plasma
stability and moderate metabolic stability. ML278 is expected




Additional SAR data; preparation and characterization of 17−
11 (ML278); probe comparison table; representative dose−
response curves of ML278 and ITX-5061 in [3H]CE uptake
assay; compound proﬁling and assay protocols; oﬀ-target
screening data. This material is available free of charge via






Funding for this work was provided in part by the NIH-
MLPCN program (1 U54 HG005032-1 awarded to S.L.S.) and
NIH grants HL052212 and HL066105 to M.K.
Notes
The authors declare the following competing ﬁnancial
interest(s): A patent application is pending for compounds
described in this manuscript.
■ ACKNOWLEDGMENTS
We thank Stephen Johnston, Carrie Mosher, Travis Anthoine,
and Mike Lewandowski for analytical chemistry support.
■ ABBREVIATIONS
Boc, tert-butoxycarbonyl; CC50, half-maximal cytotoxic concen-
tration; CE, cholesteryl ester; CETP, cholesteryl ester transfer
protein; CHO, Chinese Hamster Ovary; CYP, cytochrome
P450; DCM, dichloromethane; DCE, 1,2-dichloroethane;
DMAP, 4-(N,N-dimethylamino)-pyridine; DiI, 1,1′-dioctadec-
yl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate; EC50,
half-maximal eﬀective concentration; EtOH, ethanol; HCV,
hepatitis C virus; HDL, high density lipoprotein; HDL-C, high
density lipoprotein cholesterol; HTS, high-throughput screen;
IC50, half-maximal inhibitory concentration; MAPK, mitogen-
activated protein kinase; MLP, Molecular Libraries Program;
MLPCN, Molecular Libraries Probe Production Centers
Network; MLSMR, Molecular Libraries Small Molecule
Repository; NIH, National Institutes of Health; NO, nitric
oxide; NT, not tested; PPR, pattern recognition receptor; SAR,
structure−activity relationship; SR-BI, scavenger receptor class
B, type I; TFA, 2,2,2-triﬂuoroacetic acid; Z′,Z′-factor, a measure
of assay quality calculated from the variability of positive and
negative controls32
■ REFERENCES
(1) Boden, W. E. High-density lipoprotein cholesterol as an
independent risk factor in cardiovascular disease: assessing the data
from Framingham to the Veterans Affairs High-Density Lipoprotein
Intervention Trial. Am. J. Cardiol. 2000, 86, 19L−22L.
(2) Voight, B. F.; et al. Plasma HDL cholesterol and risk of
myocardial infarction: a mendelian randomisation study. Lancet 2012,
380, 572−580.
(3) deGoma, E. M.; Rader, D. J. Novel HDL-directed pharmacother-
apeutic strategies. Nat. Rev. Cardiol. 2011, 8, 266−277.
(4) See for example: Ranalletta, M.; et al. Biochemical character-
ization of cholesteryl ester transfer protein inhibitors. J. Lipid Res.
2010, 51, 2739−2752.
(5) Acton, S.; Rigotti, A.; Landschulz, K. T.; Xu, S.; Hobbs, H. H.;
Krieger, M. Identification of scavenger receptor SR-BI as a high density
lipoprotein receptor. Science 1996, 271, 518−520.
(6) Brown, M. S.; Goldstein, J. L. A receptor-mediated pathway for
cholesterol homeostasis. Science 1986, 232, 34−47.
(7) Rigotti, A.; Miettinen, H. E.; Krieger, M. The role of the high-
density lipoprotein receptor SR-BI in the lipid metabolism of
endocrine and other tissues. Endocr. Rev. 2003, 24, 357−387.
(8) Fioravanti, J.; Medina-Echeverz, J.; Berraondo, P. Scavenger
receptor type B, class I: A promising immunotherapy target.
Immunotherapy 2011, 3, 395−406.
(9) Guo, L.; Song, Z.; Li, M.; Wu, Q.; Wang, D.; Feng, H.; Bernard,
P.; Daugherty, A.; Huang, B.; Li, X. A. Scavenger receptor BI protects
against septic death through its role in modulating inflammatory
response. J. Biol. Chem. 2009, 284, 19826−19834.
(10) Zhu, P.; Liu, X.; Treml, L. S.; Cancro, M. P.; Freedman, B. D.
Mechanism and regulatory function of CpG signaling via scavenger
receptor B1 in primary B cells. J. Biol. Chem. 2009, 284, 22878−22887.
(11) Voisset, C.; Callens, N.; Blanchard, E.; Op De Beeck, A.;
Dubuisson, J.; Vu-Dac, N. High density lipoproteins facilitate hepatitis
C virus entry through the scavenger receptor class B type I. J. Biol.
Chem. 2005, 280, 7793−7799.
(12) Catanese, M. T.; Graziani, R.; von Hahn, T.; Moreau, M.; Huby,
T.; Paonessa, G.; Santini, C.; Luzzago, A.; Rice, C. M.; Cortese, R.;
Vitelli, A.; Nicosia, A. High-avidity monoclonal antibodies against the
human scavenger class B type I receptor efficiently block hepatitis C
virus infection in the presence of high-density lipoprotein. J. Virol.
2007, 81, 8063−71.
(13) Catanese, M. T.; Ansuini, H.; Graziani, R.; Huby, T.; Moreau,
M.; Ball, J. K.; Paonessa, G.; Rice, C. M.; Cortese, R.; Vitelli, A.;
Nicosia, A. Role of scavenger receptor class B type I in hepatitis C
virus entry: kinetics and molecular determinants. J. Virol. 2010, 84,
34−43.
(14) Papale, G. A.; Hanson, P. J.; Sahoo, D. Extracellular disulfide
bonds support scavenger receptor Class B Type I-mediated cholesterol
transport. Biochemistry 2011, 50, 6245−6254.
(15) Gaidukov, L.; Nager, A. R.; Xu, S.; Penman, M.; Krieger, M.
Glycine dimerization motif in the N-terminal transmembrane domain
of the high density lipoprotein receptor SR-B1 required for normal
receptor oligomerization and lipid transport. J. Biol. Chem. 2011, 286,
18452−18464.
(16) Yu, M.; Lau, T. Y.; Carr, S. A.; Krieger, M. Contributions of a
disulfide bond and a reduced cysteine side chain to the intrinsic
activity of the high-density lipoprotein receptor SR-BI. Biochemistry
2012, 51, 10044−10055.
(17) During the preparation of this manuscript, the x-ray crystal
structure of LIMP-2 was determined, a pattern-recognition recognition
receptor in the same CD36 superfamily as SR-BI: Neculai, D.;
Schwake, M.; Ravichandran, M.; Zunke, F.; Collins, R. F.; Peters, J.;
Neculai, M.; Plumb, J.; Loppnau, P.; Pizarro, J.-C.; Seitova, A.;
ACS Medicinal Chemistry Letters Letter
DOI: 10.1021/ml500154q
ACS Med. Chem. Lett. 2015, 6, 375−380
379
Trimble, W. S.; Saftig, P.; Grinstein, S.; Dhe-Paganon, S. Structure of
LIMP-2 provides functional insights with implications for SR-BI and
CD36. Nature 2013, 504, 172−176.
(18) Nieland, T. J.; Penman, M.; Dori, L.; Krieger, M.; Kirchhausen,
T. Discovery of chemical inhibitors of the selective transfer of lipids
mediated by the HDL receptor SR-BI. Proc. Natl. Acad. Sci. U.S.A.
2002, 99, 15422−15427.
(19) Coppola, G. M.; Damon, R. E.; Eskesen, B.; France, D. S.;
Paterniti, J. R. Biological evaluation of 1-alkyl-3-phenylthioureas as
orally active HDL-elevating agents. Bioorg. Med. Chem. Lett. 2006, 16,
113−117.
(20) Nieland, T. J.; Shaw, J. T.; Jaipuri, F. A.; Maliga, Z.; Duffner, J.
L.; Koehler, A. N.; Krieger, M. J. Lipid Res. 2007, 48, 1832−1845.
(21) Nishizawa, T.; Kitayama, K.; Wakabayashi, K.; Yamada, M.;
Uchiyama, M.; Abe, K.; Ubukata, N.; Inaba, T.; Oda, T.; Amemiya, Y.
A novel compound, R-138329, increases plasma HDL cholesterol via
inhibition of scavenger receptor BI- mediated selective lipid uptake.
Atherosclerosis 2007, 194, 300−308.
(22) Syder, A. J.; Lee, H.; Zeisel, M. B.; Grove, J.; Soulier, E.;
Macdonald, J.; Chow, S.; Chang, J.; Baumert, T. F.; McKeating, J. A.;
McKelvy, J.; Wong-Staal, F. Small molecule scavenger receptor BI
antagonists are potent HCV entry inhibitors. J. Hepatol. 2011, 54, 48−
55.
(23) Zhu, H.; Wong-Staal, F.; Lee, H.; Syder, A.; McKelvy, J.;
Schooley, R. T.; Wyles, D. L. Evaluation of ITX 5061, a scavenger
receptor B1 antagonist: resistance selection and activity in
combination with other hepatitis C virus antivirals. J. Infect. Dis.
2012, 205, 656−62.
(24) Sulkowski, M. S.; Kang, M.; Matining, R.; Wyles, D.; Johnson, V.
A.; Morse, G. D.; Amorosa, V.; Bhattacharya, D.; Coughlin, K.; Wong-
Staal, F.; Glesby, M. J. Safety and antiviral activity of the HCV entry
inhibitor ITX5061 in treatment-naive HCV infected adults: A
randomized, double-blind, Phase 1b study. J. Infect. Dis. 2014, 209,
658−667.
(25) Researchers at iTherX recently reported the structure of the
HCV entry inhibitor ITX 4520, which is postulated to act as an
inhibitor of SR-BI: Mittapalli, G. K.; Zhao, F.; Jackson, A.; Gao, H.;
Lee, H.; Chow, S.; Pal Kaur, M.; Nguyen, N.; Zamboni, R.; McKelvy,
J.; Wong-Staal, F.; Macdonald, J. E. Discovery of ITX 4520: A highly
potent orally bioavailable hepatitis C virus entry inhibitor. Bioorg. Med.
Chem. Lett. 2012, 22, 4955−4961.
(26) See Supporting Information for details.
(27) A Small Molecule Inhibitor of Scavenger Receptor BI-mediated
Lipid UptakeProbe. http://www.ncbi.nlm.nih.gov/books/
NBK133420/ (accessed March 1, 2014).
(28) Compound 5−1 was active in ﬁve assays not involving SR-B1
out of 315 bioassays listed on December 10, 2011.
(29) Kalgutkar, A. S.; Gardner, I.; Obach, R. S.; Shaffer, C. L.;
Callegari, E.; Henne, K. R.; Mutlib, A. E.; Dalvie, D. K.; Lee, J. S.;
Nakai, Y.; O’Donnell, J. P.; Boer, J.; Harriman, S. P. A comprehensive
listing of bioactivation pathways of organic functional groups. Curr.
Drug Metab. 2005, 6, 161−225.
(30) Stepan, A. F.; Walker, D. P.; Bauman, J.; Price, D. A.; Baillie, T.
A.; Kalgutkar, A. S.; Aleo, M. D. Structural alert/reactive metabolite
concept as applied in medicinal chemistry to mitigate the risk of
idiosyncratic drug toxicity: a perspective based on the critical
examination of trends in the top 200 drugs marketed in the United
States. Chem. Res. Toxicol. 2011, 24, 1345−1410.
(31) Measured with a CellTiter-Glo assay (Promega) to determine
cellular ATP levels.
(32) Zhang, J.-H.; Chung, T. D. Y.; Oldenburg, K. R. A simple
statistical parameter for use in evaluation and validation of high
throughput screening assays. J. Biomol. Screening 1999, 4, 67−73.
ACS Medicinal Chemistry Letters Letter
DOI: 10.1021/ml500154q
ACS Med. Chem. Lett. 2015, 6, 375−380
380
